期刊文献+

不同剂量蛋白酶体抑制剂对缺血后神经元的作用

Effect of Different Dose of Proteasome Inhibitor on Neuron after Ischemic Stroke
下载PDF
导出
摘要 目的:探索蛋白酶体抑制剂在不同剂量时对缺血后脑组织的作用及原因。方法:使用大鼠单侧大脑中动脉栓塞模型,50只大鼠随机分成5组,梗塞3小时后注入不同剂量的蛋白酶体抑制剂MG132,定时进行神经功能评分、TTC染色、TUNEL染色、Western blot检测Casepase 8蛋白表达。结果:MG132治疗有效缩小脑梗死体积,1mg/Kg组凋亡细胞数目最少,Casepase 8表达与MG132剂量相关。结论:蛋自酶体抑制剂对缺血区神经元的保护作用局限于低剂量效应,高剂量下对神经元有促凋亡作用。蛋白酶体抑制剂的保护作用可能通过Casepae 8途径起作用。 Objective: To investigate the Protective Effect of different doses of Proteasome Inhibitor on Neuron after Isehemic Stroke. Methods:Fifty rats were randomly divided into five groups We determinod that a potent proteasorne inhibitor. MG132 exerted therapeutic effects in experimental model of middle cerebral artery occlusion. Either MG132 (0. 5. 1, 2 mg/kg) or vehicle was intravenously administered 3 h after stroke. The cerebral infarction tissues were stained by TTC and TUNEL. Western blot analysis was used to detect the expression level of Casepase 8. Results: MG132 at 0.1 mg/kg significantly reduced ischemic tissue volume compared to the controla The numbers of TUNEL cells in the ischemic regions were decreased subsequent to MG 132 treatments. MG132 induced a significant elevation of the expression level of Casepase 8. Conclusion: Proteasome Inhibitor protects neuron in ischemic tissue at a relatively low concentration, and it is toxic to neuron at a relatively high concentration. Proteasome Inbibitor protects neuron through Casepase 8 pathway
出处 《中国医药导刊》 2009年第12期2087-2089,共3页 Chinese Journal of Medicinal Guide
关键词 蛋白酶体抑制剂 脑梗死 Casepase 8 Proleasome Inhibitor brain ischemia: Cascpase 8
  • 相关文献

参考文献12

  • 1Grzegorz Nalepa,Mark Rolfe and J.Wade Harper.Drug discovery in the ubiquitin-proteasome system[J].Nature Reviews Drug Discovery,2006;5(7):596-613. 被引量:1
  • 2Suzaune Tymacka,Chuan-En Wang,Xuejun Wang,et a1.Differential Activities of the Ubiquitin-Proteasome System in Neurons versus Glin May Account for the Preferential Accumulation of Misfolded Proteins in Neurons[J].J.Neurosci,2008;28(49):13285-13295. 被引量:1
  • 3Basis Bingol and Erin M Schuman,Synaptic protein degradation by the ubiquitin proteasome system[J].Curr.Opin.Neurobiol,2005,15(5):536-541. 被引量:1
  • 4McNaught KS,Belizaire R,Isacson O,et a1.Altered proteasomal function in sporadic Parkinson disease[J].Exp neurol,2003;179(1):38-46. 被引量:1
  • 5Sasaki M,Honmon O,Kocsis JD.A rat middle cerebral artery occlusion model and intravenous cellular delivery[J].Methods Mol Biol.2009;549:187-195. 被引量:1
  • 6黎佳思,丁素菊,毕晓莹.通心络对大鼠脑缺血-再灌模型脑保护作用的研究[J].中风与神经疾病杂志,2006,23(1):82-84. 被引量:8
  • 7Ruemmele FM,Beaulinu JF,O Conneli,et al.The susceptibility to Fas-induced apoptosis in normal enterocytes is regulated on the level of cIAP1 end 2[J].Biochem Biophys Res Commun;2002,290(4):1308-1314. 被引量:1
  • 8Zhon J,Zhang S,Choun-Nam O,et a1.Critical role of pro-apoptotic Bcl-2 family members in endrographofide-induced apoptnsis in human cancer cells[J].Biochem Pharmacol,2006;72(2):132-144. 被引量:1
  • 9Miller CP,Rudxa S,Keating MJ,et a1.Caspase-8 dependent histone acetylation by a novel proteasome inhibitor,NPI-0052:a mechanism for synergy in leukemia cells[J].Blood,2009;113(18):4289-4299. 被引量:1
  • 10Voortman J,Resonde TP,Abou El Hassan MA,et a1.TRAIL therapy in nonsmall cell lung cancer cells:sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib[J].Mol Cancer Ther.2007;6(7):2103-2112. 被引量:1

二级参考文献18

  • 1McNaught KS, Belizaire R, Jenner P, et al. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett, 2002,326(3) : 155- 158 被引量:1
  • 2McNaught KS, Belizaire R, Isacson O, et al. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol, 2003,179( 1 ) :38-46 被引量:1
  • 3McNaught KS, Olanow CW, Halliwell B, et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci,2001,2(8) :589-594 被引量:1
  • 4Rideout Hi, Larsen KE, Sulzer D, et al. Proteasomal inhibition leads to formation of ubiquitin//alpha-synuclein immunoreactive inclusions in PC12 cells. J Neurochem. 2001,78(4) :899-908 被引量:1
  • 5McNaught KS, Mytilineou C, Jnobaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem, 2002,81(2) :301-306 被引量:1
  • 6McNaught KS, Bjorklund LM, Belizaire R, et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport, 2002,13(11):1437-1441 被引量:1
  • 7Sawada H, Kohno R, Kihara T, et al. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J Biol Chem, 2004,279(11):10710-10719 被引量:1
  • 8Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst, 1990,82(13):1107-1112 被引量:1
  • 9McNaught KS, Perl DP, Brownell AL, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol, 2004, 56 (1): 149-162 被引量:1
  • 10Sadoul R, Fernandez PA, Quiquerez AL, et al. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBOJ, 1996, 15 (15):3845-3852 被引量:1

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部